We evaluated cyclosporine A (CsA) treatment in 9 patients (6 female and 3 male), 16-63 years old, with severe myasthenia gravis (MG) for a mean period of 2 years (range 16-36 months). All of the patients had been previously treated either with corticosteroids or by combined immunotherapy, and 5 needed periodic plasma exchanges. The reduction of plasmapheresis cycles in the 5 patients who needed periodic plasma exchange to mantain an acceptable quality of life showed an impressive cost-benefit analysis. During CsA treatment 7 of 9 patients improved their muscle strength and functional score. In all the patients except one the corticosteroid dosage was reduced and in 7 of the 9 patients the dose reduction was over 50% with subsequent reductio...
Abstract: Substantial therapeutic progress has been made in myasthenia gravis (MG) even before the e...
A multicenter prospective study was carried out to evaluate the efficacy of cyclosporin A (CsA) in 3...
ABSTRACT- We analyzed the experience of Unicamp Clinical Hospital with plasma exchange (PE) therapy ...
We evaluated cyclosporine A (CsA) treatment in 9 patients (6 female and 3 male), 16-63 years old, wi...
9 subjects with myasthenia gravis, chronically treated with prednisone, underwent an open clinical t...
Immunosuppressive therapy for ocular myasthenia gravis (MG) has usually consisted of systemic cortic...
Immunosuppression is the mainstay of treatment for myasthenia gravis (MG). In this paper, we review ...
Six individuals with Ullrich congenital muscular dystrophy (UCMD) and mutations in the genes-encodin...
Six individuals with Ullrich congenital muscular dystrophy (UCMD) and mutations in the genes-encodin...
Six individuals with Ullrich congenital muscular dystrophy (UCMD) and mutations in the genes-encodin...
We studied the long-term outcome of prednisone therapy in 104 patients with myasthenia gravis (MG). ...
Six individuals with Ullrich congenital muscular dystrophy (UCMD) and mutations in the genes-encodin...
Substantial therapeutic progress has been made in myasthenia gravis (MG) even before the era of mole...
Objectives Calcineurin inhibitors (CNI) are approved for the treatment of myasthenia gravis (MG) in ...
Myasthenia gravis (MG) with antibodies against the muscle-specific tyrosine kinase (MuSK abs) is oft...
Abstract: Substantial therapeutic progress has been made in myasthenia gravis (MG) even before the e...
A multicenter prospective study was carried out to evaluate the efficacy of cyclosporin A (CsA) in 3...
ABSTRACT- We analyzed the experience of Unicamp Clinical Hospital with plasma exchange (PE) therapy ...
We evaluated cyclosporine A (CsA) treatment in 9 patients (6 female and 3 male), 16-63 years old, wi...
9 subjects with myasthenia gravis, chronically treated with prednisone, underwent an open clinical t...
Immunosuppressive therapy for ocular myasthenia gravis (MG) has usually consisted of systemic cortic...
Immunosuppression is the mainstay of treatment for myasthenia gravis (MG). In this paper, we review ...
Six individuals with Ullrich congenital muscular dystrophy (UCMD) and mutations in the genes-encodin...
Six individuals with Ullrich congenital muscular dystrophy (UCMD) and mutations in the genes-encodin...
Six individuals with Ullrich congenital muscular dystrophy (UCMD) and mutations in the genes-encodin...
We studied the long-term outcome of prednisone therapy in 104 patients with myasthenia gravis (MG). ...
Six individuals with Ullrich congenital muscular dystrophy (UCMD) and mutations in the genes-encodin...
Substantial therapeutic progress has been made in myasthenia gravis (MG) even before the era of mole...
Objectives Calcineurin inhibitors (CNI) are approved for the treatment of myasthenia gravis (MG) in ...
Myasthenia gravis (MG) with antibodies against the muscle-specific tyrosine kinase (MuSK abs) is oft...
Abstract: Substantial therapeutic progress has been made in myasthenia gravis (MG) even before the e...
A multicenter prospective study was carried out to evaluate the efficacy of cyclosporin A (CsA) in 3...
ABSTRACT- We analyzed the experience of Unicamp Clinical Hospital with plasma exchange (PE) therapy ...